Search Results
Your search for The ASCO ,The ASCO matches 20581 pages
Showing 4801 - 4850FDA Pipeline: Recent Designations in NSCLC, Leukemia, and Lymphoma
Recently, the U.S. Food and Drug Administration (FDA) issued regulatory decisions related to treatments for non–small cell lung cancer (NSCLC), acute leukemia, and mantle cell lymphoma. Breakthrough Therapy Designation for Adagrasib in Advanced NSCLC With KRAS G12C Mutation On June 24, 2021, the...
FDA Approves Alternative to E coli–Derived Asparaginase for Leukemia and Lymphoma
On June 30, 2021, the U.S. Food and Drug Administration (FDA) approved asparaginase Erwinia chrysanthemi (recombinant)-rywn (Rylaze) as a component of a multiagent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in adult and pediatric...
Modified FOLFIRINOX Established as Preferred Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer
In the treatment of borderline resectable pancreatic ductal adenocarcinoma, the Alliance A021501 trial established neoadjuvant treatment with modified FOLFIRINOX (fluorouracil [5-FU], leucovorin, irinotecan, oxaliplatin) as a new benchmark. However, it failed to show the benefit of adding...
Association Between Increased BMI and Endometrial Cancer Risk in Asian Women With Postmenopausal Bleeding
The link between obesity and the risk of endometrial cancer has been well documented. A recent study, however, showed that an even lower body mass index (BMI) than previously thought may be associated with an increased risk in Asian women with postmenopausal bleeding. The findings by Liu et al were ...
Study Examines Impact of COVID-19 on Breast and Cervical Cancer Screening Programs
The total number of cancer screening tests received by women through the Centers for Disease Control and Prevention’s (CDC) National Breast and Cervical Cancer Early Detection Program (Early Detection Program) declined by 87% for breast cancer and 84% for cervical cancer during April 2020 as...
Survey Finds COVID-19 Vaccine Hesitancy Among Many Adolescent and Young Adult Cancer Survivors
Despite recommendations from ASCO and other national organizations that cancer survivors, as well as patients on active treatment, receive the COVID-19 vaccine if they have no contraindications, a survey of adolescent and young adult cancer survivors finds many have vaccine hesitancy. According to...
Study Examines Mechanisms of Resistance in Early-Stage Breast Cancer After Endocrine Plus CDK4/6 Therapy
About 80% of breast cancer cases are hormone receptor–positive, according to the American Cancer Society. Patients with estrogen receptor–positive breast cancer generally are treated using therapy that inhibits both estrogen levels and cell-cycle activity, but about 90% of patients with metastatic...
Immunotherapy May Be Effective for Subset of Patients With Prostate Cancer
In recent years, cancer immunotherapy has been effective in treating patients with immunogenic—or “hot”—tumors with increased levels of inflammation and the presence of immune cells in and around the tumors. Prostate cancer, however, is considered a “cold” tumor, with few immune cells recognizing...
Are Patients With Primary Lung Cancer Detected by Low-Dose CT at Reduced Risk of Brain Metastases?
Patients with primary lung cancer detected using low-dose computed tomography (CT) screening may be at reduced risk for developing brain metastases after diagnosis, according to a study published in the Journal of Thoracic Oncology. The researchers, led by Summer Han, PhD, of Stanford University...
FDA Encourages Inclusion of Patients With Incurable Cancers in Oncology Clinical Trials Regardless of Prior Therapies
On June 24, 2021, Richard Pazdur, MD, Director of the U.S. Food and Drug Administration’s Oncology Center of Excellence and Acting Director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research, made the following statement: “Today, the FDA issued a draft...
News in Genitourinary Cancers From the 2021 ASCO Annual Meeting
This week, we’re focusing on new research in genitourinary cancers presented at the 2021 ASCO Annual Meeting, including renal cell carcinoma and bladder cancer.
Biden Administration Reverses Rule Limiting Access to Equitable Cancer Care for Sexual and Gender Minority Community
On May 10, 2021, the Department of Health and Human Services’ (HHS) Office for Civil Rights announced that its ban on sex discrimination once again includes a ban on discrimination on the basis of sexual orientation and gender identity. The move will reverse a final rule from June 2020 that...
ASCO-ACCC Piloting Project to Test Tools to Diversify Cancer Clinical Trials
In a continuation of their collaboration to increase clinical trial participation among patients from underrepresented racial and ethnic groups, ASCO and the Association of Community Cancer Centers (ACCC) recently announced plans to test a research site assessment tool and implicit bias training...
Watch Now: Discussion on Eligibility Criteria and the Impact on Access to Clinical Trials
On Friday, April 9, 2021, ASCO and Friends of Cancer Research (Friends) co-hosted a live virtual event, which brought together experts from across the health-care sector to discuss the recent release of the new ASCO-Friends recommendations for modernizing eligibility criteria to improve patient...
ASCO Releases Recommendations for Management of Salivary Gland Malignancies
Given the rarity of salivary gland malignancies—neoplasms that account for less than 1% to 5% of all head and neck cancers—limited evidence exists to support informed treatment guidance. The overall variability in the biologic behaviors of these neoplasms has further complicated clinical...
New ASCO Journal Series Examines Disparities in Cancer Care for Black People in the United States
A new special series in JCO Oncology Practice explores the causes of disparities in cancer care and outcomes for Black people in the United States and examines potential solutions to begin to achieve health equity for this population. The “Disparities in Cancer Care for Black People in the United...
Emerging Reasons for Optimism in Lung Cancer
Despite public smoking cessation initiatives and improved methods for early detection and treatment, lung cancer persists as the leading cause of cancer death in both men and women in the United States. However, over the past decade, smoking cessation efforts, increased screening, and new...
How to Talk With Teens and Young Adults About Their End-of-Life Goals
Although death rates for adolescent and young adults (AYAs) with cancer have been dropping 0.8% a year from 2009 to 2018, cancer remains a leading disease-related cause of death among this patient population. This year, the National Cancer Institute (NCI) estimates that 88,260 AYAs, defined by the...
PI3K Inhibition With Copanlisib Plus Rituximab in Relapsed Indolent Non-Hodgkin Lymphoma
Better understanding of the mechanism behind the malignant transformation of B cells has led to an explosion of “targeted” therapy. With the growing knowledge of the role of the B-cell receptor and its downstream kinases, it appeared that we were entering a new era in the management of patients...
Sidney Kimmel Cancer Center–Jefferson Health Names Andrew Aplin, PhD, Deputy Director for Scientific Strategy
Andrew E. Aplin, PhD, has been appointed Deputy Director for Scientific Strategy of the Sidney Kimmel Cancer Center (SKCC)–Jefferson Health. Dr. Aplin, who is Associate Director for Basic Research at SKCC and the Kalbach-Newton Professor in Cancer Research, assumed the role on June 1, 2021. As...
NIH Names Marie A. Bernard, MD, Chief Officer for Scientific Workforce Diversity
National Institutes of Health (NIH) Director Francis S. Collins, MD, PhD, has selected Marie A. Bernard, MD, as NIH’s next Chief Officer for Scientific Workforce Diversity (COSWD). Dr. Bernard will lead NIH’s effort to promote diversity, inclusiveness, and equity throughout the biomedical research...
Expert Point of View: Rui-Hua Xu, MD, PhD
David Cunningham, MD, Consultant Medical Oncologist, Head of the Gastrointestinal and Lymphoma Unit, and Director of Clinical Research at The Royal Marsden in London and Surrey in the United Kingdom, discussed CheckMate 6481 as well as the ESCORT-1st study of the PD-L1 inhibitor camrelizumab in...
CheckMate 648: First-Line Nivolumab Regimens Improve Survival in Esophageal Squamous Cell Carcinoma
As first-line treatment of advanced esophageal squamous cell carcinoma, nivolumab-containing regimens improved overall survival over standard-of-care chemotherapy, according to the first results of the global phase III CheckMate 648 trial presented at the 2021 ASCO Annual Meeting by Ian Chau, MD,...
Expert Point of View: Kunle Odunsi, MD, PhD, and Lilian T. Gien, MD, MSc
Comments on the OUTBACK trial were provided by invited discussant Kunle Odunsi, MD, PhD, Professor of Obstetrics and Gynecology, Dean for Oncology, and Director of the University of Chicago Medicine Comprehensive Cancer Center. Lilian T. Gien, MD, MSc, Associate Professor of Oncology at the...
Gauri Varadhachary, MD, Compassionate Leader, Caring and Brilliant Physician, Dies at 52
Gauri Varadhachary, MD, Clinical Professor in Gastrointestinal (GI) Medical Oncology at The University of Texas MD Anderson Cancer Center, died on June 5, 2021. She was 52. A member of the MD Anderson community for nearly 20 years, Dr. Varadhachary was remembered for her dedication to her patients, ...
Dana-Farber and Harvard Street Neighborhood Health Center to Connect Patients to Cancer Services
Dana-Farber Cancer Institute and Harvard Street Neighborhood Health Center (HSNHC) in Dorchester, Massachusetts, have entered into an agreement to connect patients to cancer prevention, education, diagnosis, and treatment services. This program, based out of Dana-Farber’s Cancer Care Equity...
Breast Cancer Has Taught Me Many Life Lessons
In 2016, 2 years before I was diagnosed with stage III estrogen and progesterone receptor–positive, HER2-negative, invasive ductal carcinoma in situ in my left breast, I had felt a mass in my right breast that turned out to be a benign fibroid. When I felt a mass in my left breast one morning while ...
Addressing Sexuality Challenges Throughout the Cancer Care Continuum
Multiple studies have shown that sexuality and intimacy problems are common among patients with cancer, often beginning at the time of diagnosis and persisting through the continuum of care into the survivorship setting. Although these problems have been well documented, many patients and survivors ...
Pancreatic Cancer Center of Excellence to Leverage Research and Clinical Care Innovations for Patients
The University of North Carolina (UNC) Lineberger Comprehensive Cancer Center has established the Pancreatic Cancer Center of Excellence to bring together cancer center faculty with a broad range of expertise—from laboratory, translational, and clinical research to drug development, biostatistics,...
MD Anderson and Broad Institute Launch New Translational Research Platform Focused on Rare Cancers
The University of Texas MD Anderson Cancer Center and the Broad Institute of MIT and Harvard recently announced the launch of a new translational research platform to study rare cancers and develop a first-of-its-kind resource for the scientific community. The joint initiative will create a catalog ...
John D. Carpten, PhD, FAACR, to Join the AACR Board of Directors
The American Association for Cancer Research (AACR) recently announced that John D. Carpten, PhD, FAACR, has been elected by the association to serve on its Board of Directors. Dr. Carpten has accepted the position previously held by Karen E. Knudsen, MBA, PhD, who is stepping down to fulfill her...
Inaugural Vice Chair for Diversity & Health Equity Appointed by NYU Langone/NYU Grossman School of Medicine
New York University (NYU) Langone/NYU Grossman School of Medicine recently announced that Kathie-Ann Joseph, MD, MPH, has been promoted to the rank of Professor in Surgery. Dr. Joseph has also assumed the rank of Professor in Population Health. In addition, Dr. Joseph has been named the inaugural...
Newly Diagnosed Multiple Myeloma
“Continuous improvement is better than delayed perfection.” —Mark Twain To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on...
Innovator in Treatment of Infectious Diseases, Francisco Marty, MD, Dies at 53
The Brigham and Women’s hospital community mourns the loss of Francisco Marty, MD, of the Division of Infectious Diseases, who died April 8, 2021, after a tragic accident while hiking in the Dominican Republic. He was 53. A member of the Brigham community for more than 20 years, Dr. Marty is...
OUTBACK: No Benefit for Adjuvant Chemotherapy in Cervical Cancer
In women with locally advanced cervical cancer, adjuvant chemotherapy adds no benefit to standard cisplatin-based chemoradiation, results of the international phase III OUTBACK study have shown,1 as reported at the 2021 ASCO Annual Meeting by Linda R. Mileshkin, MD, Professor of Medical Oncology at ...
Do Community Oncologists Have Access to Geriatric Specialty Care for Older Patients?
As our population rapidly ages, the burden of cancer incidence increases accordingly, creating an urgent need for greater and more incisive research on the diagnosis, treatment, and survivorship issues for older adults with cancer. Given the numerous challenges faced by today’s busy oncologists, a...
Expert Point of View: Rana R. McKay, MD
Invited discussant of the KEYNOTE-564 trial, Rana R. McKay, MD, Associate Professor of Medicine and Urology at the University of California San Diego, offered these comments about these trial results. “This is a positive study, showing a 32% reduction in the risk of recurrence or death with...
KEYNOTE-564: Adjuvant Pembrolizumab Extends Disease-Free Survival in High-Risk Renal Cell Carcinoma
Adjuvant pembrolizumab following surgery significantly improved disease-free survival compared with placebo among patients with high-risk clear cell renal cell carcinoma (RCC), according to the international phase III KEYNOTE-564 study presented at the Plenary session during the 2021 ASCO Annual...
Cancer in Morocco: Access to Innovative Treatments and Research Status
Morocco is an Arab country in North Africa. It covers 716,550 square kilometers and has a population of nearly 36 million. The median age is 29.3 years. Morocco’s estimated gross domestic product (GDP) in 2019 was $122 million. As of 2019, Morocco’s health budget was equivalent to 4.5% of the total ...
Whispers Over My Shoulder
When I interviewed for my current post as a first-time consultant in medical oncology in the United Kingdom, I was asked about my 5-year career plan. I remember some detail of my reply, but I don’t think it even remotely encompassed the depth of insight I would gain from the patients I’ve treated...
Expert Point of View: Mark G. Kris, MD, FASCO
Mark G. Kris, MD, FASCO, Chief of the Thoracic Oncology Service and the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, New York, commented on the excitement in the field of lung cancer about the new drugs targeting KRAS. Sotorasib is one of several new...
Young Urologist of the Year Award Winners
Established by Michael C. Ost, MD, MBA, the 2012–2013 American Urological Association Young Urologists Committee Chair, the Young Urologist of the Year Award is presented annually to select early-career association members in recognition of their efforts and commitment to advancing the development...
AACR CEO Margaret Foti, PhD, MD (hc), to Receive Gallery of Success Award From Temple University
Margaret Foti, PhD, MD (hc), Chief Executive Officer (CEO) of the American Association for Cancer Research (AACR), has been selected as a Temple University Gallery of Success honoree for 2021. Each year, Temple University showcases exceptional alumni from its 17 schools and colleges in its Gallery...
Cynthia M. Yoshida, MD, Honored Nationally for Increasing Colorectal Cancer Screening Rates
Cynthia M. Yoshida, MD, is one of six winners of a national award recognizing health-care providers and institutions for their work to increase colorectal cancer screening rates. Dr. Yoshida, a gastroenterologist and medical leader of the University of Virginia (UVA) Cancer Center’s Colorectal...
Chanita Hughes-Halbert, PhD, to Advance Cancer Equity at USC Norris Comprehensive Cancer Center
Chanita Hughes-Halbert, PhD, will join the University of Southern California (USC) Norris Comprehensive Cancer Center as Associate Director for Cancer Equity, a newly created position, and the Keck School of Medicine of USC as Professor and Vice Chair of Research in the Department of Preventive...
Mary Daly, MD, PhD, FACP, Receives NCCN’s 2021 Rodger Winn Award
The National Comprehensive Cancer Network (NCCN) recently presented Mary B. Daly, MD, PhD, FACP, Professor in the Department of Clinical Genetics and Director of the Risk Assessment Program at Fox Chase Cancer Center, with the Rodger Winn Award. The Rodger Winn Award is given annually to one NCCN...
Harnessing a Worldwide Effort to Combat COVID-19 and Cancer
This past October, in a virtually held ceremony of the General Assembly of the Union for International Cancer Control (UICC), Anil K. D’Cruz, MBBS, MS, DNB, FRCS (Hon), Director of Oncology at Apollo Hospitals in Mumbai, Chennai, and Delhi, India, began his 2-year tenure as President of the global...
Sotorasib: Subgroup Analysis of Phase II Trial Shows Activity With Breakthrough KRAS Inhibitor in Lung Cancer
The breakthrough KRAS-specific inhibitor sotorasib achieved responses in patients with KRAS G12C–mutated non–small lung cancer (NSCLC) who had experienced disease progression on platinum-based chemotherapy, immunotherapy, or both treatments. The objective response rate was 37.1%, and responses...
How RAS Mutations in Early-Onset Colorectal Cancer May Impact Patient Survival
Although both incidence and mortality rates in colorectal cancer have been declining among people older than 65 by 3.3% and 3% annually, respectively, among individuals younger than age 50, the incidence rate has risen about 2% annually, and death rates have increased by 1.3% annually.1 Colorectal...
Lessons From Pneumococcal Vaccine Responses in Patients With CLL in an Evolving Vaccine Landscape
The role of vaccines in mitigating the significant morbidity and mortality associated with infections in chronic lymphocytic leukemia (CLL) is a developing field of study, punctuated by the advent of novel therapeutic agents and pressing questions regarding the global SARS–CoV-2 vaccination...
